miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

Table 1 Ovarian cancer patient characteristics

	Histological subtype	FIGO stage	Grade	Cytotoxic agents used	Response to last Pt containing treatment
Patient 1	Serous	IV	2	Carboplatin, Paclitaxel	PD within 1 month
Patient 2	Serous	IIIc	UK	Carboplatin, Paclitaxel, Gemcitabine	PD within 4 months
Patient 3	Serous	IIIc	3	Carboplatin, Paclitaxel, Gemcitabine	PD within 1 month
Patient 4	Serous	IIIc	2	Carboplatin, Paclitaxel, Olaparib, Caelyx	PD during treatment
Patient 5	Clear cell	IIIc	3	Carboplatin, Ifosfamide	PD within 1 month
Patient 6	Serous	IIIc	3	Carboplatin, Paclitaxel, Caelyx	PD within 5 months
Patient 7	Serous	IIIc	2		Chemotherapy naive

UK: Unknown, Pt: Platinum, PD: Progressive disease, Caelyx: liposomal doxorubicin

ISSN: 1476-4598